Get the Stockscreener App
8.03
0.75%
0.06
After Hours:
8.03
Amylyx Pharmaceuticals Inc stock is traded at $8.03, with a volume of 1.16M.
It is up +0.75% in the last 24 hours and up +25.27% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$7.97
Open:
$7.94
24h Volume:
1.16M
Relative Volume:
0.82
Market Cap:
$715.80M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
11.47
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
-3.25%
1M Performance:
+25.27%
6M Performance:
+120.00%
1Y Performance:
+289.81%
1-Day Range:
$7.84
$8.29
1-Week Range:
$7.84
$8.30
52-Week Range:
$1.76
$8.72
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
8.03 | 710.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals Announces Q2 2025 Earnings Call: Here's How to Join the Discussion - Stock Titan
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
What is the dividend policy of Amylyx Pharmaceuticals Inc. stockEarnings Report Alerts For Every Investor - jammulinksnews.com
What institutional investors are buying Amylyx Pharmaceuticals Inc. stockSwing Trade Report To Watch Now - jammulinksnews.com
Can trapped investors hope for a rebound in Amylyx Pharmaceuticals Inc.Step-by-Step Trade Signal Implementation Guide Ready - metal.it
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 - MSN
Elliott Wave Theory Predicts Pullback in Amylyx Pharmaceuticals Inc.Weekly Stock Watch With Growth Focus Expanded - metal.it
How Amylyx Pharmaceuticals Inc. stock reacts to Fed policy changesSafe Entry Stock Watch Suggestions for Cautious Traders - metal.it
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionSector Rotation Based Trading Opportunities Identified - metal.it
What are analysts’ price targets for Amylyx Pharmaceuticals Inc. in the next 12 monthsStrong return on investment - jammulinksnews.com
Is it the right time to buy Amylyx Pharmaceuticals Inc. stockTrack top-performing stocks in real-time - jammulinksnews.com
What are the technical indicators suggesting about Amylyx Pharmaceuticals Inc.Get exclusive market insights for better trading - jammulinksnews.com
Is Amylyx Pharmaceuticals Inc. a growth stock or a value stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How many analysts rate Amylyx Pharmaceuticals Inc. as a “Buy”Maximize returns with smart investment plans - jammulinksnews.com
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community with 300% Return - metal.it
What catalysts could drive Amylyx Pharmaceuticals Inc. stock higher in 2025Unlock real-time stock alerts for quick profits - jammulinksnews.com
What are Amylyx Pharmaceuticals Inc. company’s key revenue driversExponential return rates - jammulinksnews.com
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyAchieve consistent profits with disciplined trading - jammulinksnews.com
Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia
Is Amylyx Pharmaceuticals Inc. a good long term investmentConsistent high-yield stocks - PrintWeekIndia
What analysts say about Amylyx Pharmaceuticals Inc. stockConsistently superior profits - PrintWeekIndia
Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com
What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com
Published on: 2025-07-22 15:57:30 - jammulinksnews.com
autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional
Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):